Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis

doi:10.12998/wjcc.v10.i18.6091

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 18

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5780)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-3) series.

Item

Count

PDF

235

WORD

HTML

3340

Figures (1-6)

384

Tables (1-3)

296

Sum=4317

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

351

Download

1112

Sum=1463

Jun 26, 2022 (publication date) through Dec 25, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Clin Cases. Jun 26, 2022; 10(18): 6091-6104
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6091

Full Size Figure Download Figure

Figure 1 Flow chart for literature search. IFX: Infliximab; ADA: Adalimumab; CTZ: Certolizumab; CD: Crohn’s disease; UC: Ulcerative colitis.

Citation: Yang HH, Huang Y, Zhou XC, Wang RN. Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis. World J Clin Cases 2022; 10(18): 6091-6104
URL: https://www.wjgnet.com/2307-8960/full/v10/i18/6091.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i18.6091